Acceleron Pharma Inc.

Unlock to Claim this listing
Add / Modify Company

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space.

Click to rate this company
[Total: 0 Average: 0]

3.2

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

Research Impact: Acceleron’s focus on drug discovery and development could indirectly contribute to environmental sustainability by advancing treatments that improve patients’ health and reduce the overall burden on healthcare systems. Efficient Operations: The company may focus on efficient use of resources in its operations, such as energy-efficient facilities and sustainable supply chain practices.Acceleron’s core business of developing therapies could have a significant positive impact on patient health and well-being, addressing unmet medical needs. Healthcare Access: The company’s focus on rare and serious diseases could contribute to accessible and advanced healthcare solutions.Clinical Standards: Adherence to ethical and clinical standards is essential for maintaining patient trust and regulatory compliance in drug development. Transparency: Acceleron’s commitment to transparency and ethical conduct likely reflects in its corporate governance practices.Acceleron’s financial sustainability comes from the development and potential commercialization of innovative therapies. Investor Relations: The company’s ESG efforts can influence investor perception, especially for those seeking investments aligned with ethical healthcare innovations.Acceleron’s therapies directly impact patient lives by addressing serious medical conditions and improving health outcomes. Investors: The company’s ESG initiatives can resonate with investors interested in both financial returns and ethical medical advancements.

Eligible Awards

Coming Soon

Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$92,500,000.00

Website Traffic

Employee Rating

4.8

Customer Rating

4.2

Company Size

100-1000

ESG Risk Rating

3

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.